Investigators examine the role of miRNAs in migraine, including understanding its pathogenesis, the population at risk, diagnosis, patient stratification, chronification risk factors, response to treatments, and miRNA-based therapeutic options.
In Denmark, investigators found data that showed many factors that were linked to treatment-resistant depression, including cohabitation, migraine, and so on.
The presence of migraine and increasing headache pain intensity are associated with higher rates of anxiety, depression, inflammation, and sleep conditions, among other disorders.
The FDA has accepted for review the NDA for Qtrypta™ (zolmitriptan intracutaneous microneedle system; Zosano Pharma) for the acute treatment of migraine.
The Food and Drug Administration (FDA) has approved Nurtec™ ODT (rimegepant; Biohaven) for the acute treatment of migraine with or without aura in adults.
